# Andreas Wollenberg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andreas-wollenberg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,469 |
| Field | Dermatology and Skin Diseases |
| h-index | 81 |
| i10-index | 278 |
| Last Known Institution | University Hospital Augsburg |
| OpenAlex ID | https://openalex.org/A5073722593 |
| ORCID iD | 0000-0003-0177-8722 |
| Works | 570 |

## Researcher papers

Showing 12 of 25.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I](https://scholariq.org/papers/consensus-based-european-guidelines-for-treatment-of-atopic-eczema-atopic/)
- [Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II](https://scholariq.org/papers/consensus-based-european-guidelines-for-treatment-of-atopic-eczema-atopic-2/)
- [Guidelines for treatment of atopic eczema (atopic dermatitis) Part I](https://scholariq.org/papers/guidelines-for-treatment-of-atopic-eczema-atopic-dermatitis-part-i/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis](https://scholariq.org/papers/anti-interleukin-31-receptor-a-antibody-for-atopic-dermatitis/)
- [Cellular and molecular immunologic mechanisms in patients with atopic dermatitis](https://scholariq.org/papers/cellular-and-molecular-immunologic-mechanisms-in-patients-with-atopic-dermatitis/)
- [Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-abrocitinib-in-adults-and-adolescents-with-moderate-to/)
- [Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI).](https://scholariq.org/papers/human-epidermal-langerhans-cells-express-the-high-affinity-receptor-for/)
- [ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children](https://scholariq.org/papers/etfad-eadv-eczema-task-force-2020-position-paper-on-diagnosis-and-treatment-of/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy](https://scholariq.org/papers/european-guideline-euroguiderm-on-atopic-eczema-part-i-systemic-therapy/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Researcher university

- [University Hospital Augsburg](https://scholariq.org/institutions/university-hospital-augsburg/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.